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Background: Tanzania adopted artemether-lumefantrine (AL) as first-line drug for uncomplicated malaria in 2006.
Recently, there was an anecdotal report on high malaria recurrence rate following AL treatment in in the (urban
and peri-urban), western part of Tanzania. The current report is an exploratory study to carefully and systematically
assess AL efficacy in the area.
Methods: Between June and August 2011, a total of 1,126 patients were screened for malaria, 33 had malaria, of
which 20 patients met inclusion criteria and were enrolled and treated with standard dose of AL as recommended
in the WHO protocol. Treated patients were followed up for 28 days to assess treatment responses. Before
treatment (Day 0) and post-treatment (Day 7) plasma lumefantrine levels were determined to assess prior AL use
and ascertain parasites exposure to adequate plasma leveles of lumefantrine, respectively.
Results: The cure rate was 100%. All Day 0 plasma lumefantrine were below HPLC detectable level. The median
Day 7 lumefantrine concentration was 404, (range, 189–894 ng/ml). Six out of 20 patients (30%) were
gametocytaemic and all cleared gametocytes by Day 14. One patient showed an increase in gametocytes from four
on Day 0 to 68, per 500 WBC on Day 2.
Conclusion: Artemether lumefantrine is highly efficacious against uncomplicated Plasmodium falciparum malaria.
The elevation of gametocytaemia despite AL treatment needs to be evaluated in a larger study.Background
The adoption of artemisinin-based combination therapy
(ACT) in sub-Saharan Africa as first-line drug for
the treatment of uncomplicated malaria [1] was largely
based on experience gained in low transmission areas of
Southeast Asia using artesunate-mefloquine (AS-MQ) [2].
The few studies conducted in sub-Saharan Africa prior to
adoption of AS+AQ and AL recorded nearly 100% cure
rate [3,4]. However, the long-term impact and extended
useful therapeutic life of these drug combinations in high
transmission areas remains unclear. Already increased
parasite clearance half-life and reduced susceptibility to* Correspondence: kmugittu@ihi.or.tz
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reproduction in any medium, provided the orartemisinins and artesunate-mefloquine has been reported
in Thai-Cambodia and Thai-Myanmar boarder [5,6]. In-
deed there is now both phenotypic [7] and genetic [8]
evidence of artemisinin resistance in these areas. It is
hypothesized that if not controlled, artemisinin resistance
might eventually spread all over the malaria-endemic
world. Thus WHO recommends increased monitoring
and surveillance to evaluate the threat of artemisinin re-
sistance and identify new foci rapidly and to provide infor-
mation for immediate and comprehensive containment
and prevention activities. Therefore, this exploratory study
was carried out as an action plan in response to reports of
high recurrent rate following AL treatment in Tabora,
western Tanzania (pers comm, Dr Ruth Hulser, St Phillip’sLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Study profile. Key: “Complete study” represents children
who had been followed up to Day 28; ETF = early treatment failure;
LCF = late clinical failure; LPF = late parasitological failure; ACPR =
adequate clinical and parasitological responses; BS = blood smear.
Table 1 Baseline characteristics of the study participants
n Minimum Maximum Mean Std Deviation
Age (months) 20 6.00 59.00 39.3500 18.65
Weight (Kg) 20 6.7 23.4 14.9 4.5
Temp(0C) 20 35.3 39.7 37.8 1.4
Par./200 wbc 20 56 3577 985 986
Parasites/μl 20 2240 143,080 39,400 39450
Hb (g/dl) 20 6.3 12.9 9.1 1.7
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AL resistance in the region.
Methods
Study site, design, sampling frame and sample size
An in vivo study was carried out between mid-June and
mid-August 2011 at Kitete Regional Hospital and St.
Philip’s and St Anne’s health facilities serving the urban
and peri-urban areas of Tabora municipality. Tabora is a
high-burden area and malaria transmission peaks during
the rain season, i.e., February to May [9]. Children aged
six to 59 months reporting to the hospital with fever or
history of fever underwent physical and clinical exami-
nation by the study clinician. Inclusion and exclusion
criteria are as described in the WHO protocol for high
transmission areas [10]. The recruited patients were
treated under supervision with a standard six doses of
dispersible formulation of AL (CoartemW, Novartis) with
full cream milk. The first dose was given at the health
centre by a study nurse or clinician and the subsequent
doses were given at home by a parent or guardian and
monitored by study personnel through mobile phone
call or home visits if the parent/guardian was not reach-
able by mobile phone. Three children vomited within 30
min of first dose and replacement dose was given and
no patient vomited a replaced dose.
The clinical and parasitological responses were assessed
on Day 2, 3, 7, 14, 21 and 28 during the 28-day follow-up
period. Parasitological responses were assessed microscop-
ically by counting against 200 or 500 white blood cells for
asexual and sexual (gametocytes), respectively. Gameto-
cytes were not staged. Admittedly, one major limitation is
that microscopy understimates the prevalence of gameto-
cytes. Plasma lumefantrine levels were determined before
treatment (Day 0) and post-treatment (Day 7). In the three
months, of 1,126 children screened 33 had malaria and
only 20 met the inclusion criteria and were recruited
(Figure 1), following the recommendations of at least 12
patients per treatment for an exploratory study [11]. The
primary efficacy endpoints were classified as: early
treatment failure (ETF), late clinical failure (LCF), late
parasitological failure (LPF) and adequate clinical and
parasitological response (ACPR) on 28 days’ follow-up
period [12]. There was no loss to follow up despite the fact
that some patients came as far as 10 km away from the
health facilities.
Determination of plasma lumefantrine levels
From each recruited patient, 2 ml venous blood was col-
lected into heparinized vacutainers on Day 0 and Day 7
for plasma drug level determination. The plasma was
separated from blood cells by centrifugation, transferred
into 2 ml cryovials and stored in liquid nitrogen. All
plasma samples were sent to Muhimbili University Collegeof Health and Allied Sciences (MUHAS) laboratory for
lumefantrine level analysis by high performance liquid
chromatographic (HPLC) method as described [12].
The study protocol was reviewed and approved by
Ethical Review Committee of the Ifakara Health Institute
(IHI) and MUHAS. Prior to the trial, a written consent
form was signed by the parent or guardian of each par-
ticipating child.Results
Study profile and treatment outcome
A total number of 1,126 patients were screened from
the three health facilities in Tabora region as follows:
St Philip’s Health Centre: n= 663; St Anne’s Health
Centre: n=345; and, Kitete Regional Hospital: n=118.
The baseline characteristics of the study participants are
indicated in Table 1.
Twenty-four (24) out of 663 (3.6%), five out of 345
(1.4%) and four out of 118 (3.4%) patients in St Phillip’s,
St Anne’s Health Centres and Ketete Hospital, respect-
ively, were positive for malaria parasites by microscopy.
Comparison of routine (before the study) and expert
(during the study) malaria diagnosis was done. The rou-
tine and expert malaria microscopy results recorded in
Table 2 Haemoglobin levels on Day 0 and Day 7
N Minimum Maximum Mean Std Deviation
Day 0 Hb(in g/dl) 20 6.30 12.9 9.14 1.69
Day 7 Hb (g/dl) 20 6.90 12.70 9.64 1.62
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positive n=176) of June 2011, respectively, were signifi-
cantly different (p < 0.005). Only 20 patients met the
inclusion criteria and were enrolled. Patients were trea-
ted and assessed for treatment outcome without loss of
follow up as detailed in Figure 1. The cure rate of the
drug was 100%. Table 2 shows that the mean haemoglo-
bin was significantly increased, from 9.1 (±1.69) g/dL on
Day 0 to 9.6 g/dL (±1.62) on Day 7 (p=0.048).Plasma lumefantrine levels of patients
The lumefantrine plasma concentrations measured in
patients before drug administration in all 20 enrolled
patients were below HPLC detection level. The median
Day 7 lumefantrine concentration level was 404.4 ng/ml
(range 189.4-894.3 ng/ml). Only four (20%) patients had
lumefantrine plasma concentration level < 280 ng/ml,
and no patient had lumefantrine plasma concentration
level <175 ng/ml. Lumefantrine concentration at day 7
was slightly decreased with unit increase in weight (kg)
for any age but this decrease was not statistically signifi-
cant (p-value = 0.445).Gametocyte prevalence
Table 3 shows gametocytaemia before and after AL treat-
ment. Six of the 20 patients (30%) had gametocytes under
microscopic observation on Day 0 and all were above 36
months of age. In five patients the gametocytes persisted
up to Day 7 after treatment and one patient had gameto-
cytes up to Day 14 and one had gametoctes only on Day 0.
One patient showed an increase in gametocytes after treat-
ment from four gametocytes per 500 WBC on Day 0 to 68
gametocytes per 500 WBC on Day 2 followed by a de-
crease on subsequent days after treatment. No gameto-






Day 0 Day 2 Day
1 59 7 0 0
3 48 4 68 43
4 59 145 123 85
10 50 6 4 5
16 36 13 10 7
20 59 11 3 2Discussion
Artemisinins are known to be highly potent anti-malarial
drugs that are active against immature gametocytes
[13,14], hence pivotal in reduction of malaria transmission
and elimination/eradication agenda. To the best of
authors’ knowledge, there is no evidence of clinical resis-
tance to AL. However tolerance or increased parasite
clearence time and reduced susceptibility to artemisi-
nins and artesunate-mefloquine has been observed in
Thai-Cambodia and Thai-Mynmar boarder [5,6]. This is
the same locus where chloroquine resistance first emerged
and subsequently spread all over the world. Emergence of
artermisinin resistance would be disastrous for global mal-
aria control. Therefore, regular surveillance and prompt
response to any indication of compromised efficacy is
required [15].
This study recorded high (100%) efficacy of AL. The
reported efficacy level is more or less similar to >98%
recorded in Tanzania, prior to introduction of AL [4],
and elsewere in Africa [16-20]. However, in these other
studies, the high efficacy rates were reached after exclu-
sion of new infection by molecular genotyping. There-
fore, it is obvious that the cause of alarm that prompted
this exploratory study in Tabora was not malaria recur-
rence or compromised AL efficacy but malaria overdiag-
nosis. This practice has been reported previously
elsewhere in Africa [21,22] as a cause of inappropriate
malaria case managment [23]. Overdiagnosis is attribut-
able to incompetency of laboratory workers, work over-
load, and pressure from patients with fever accepting
malaria diagnosis [21].
In this study, none of the patients reported to have
taken AL prior to hospital presentation, which was con-
firmed by lack of lumefantrine traces in the plasma. In
addition, all patients had adequate therapautic levels
of lumefantrine on Day 7. However, the Day 7 plasma
lumefantrine levels showed wide variation between indi-
viduals. Indeed, it is known that the efficacy of AL com-
bination is strongly influenced by wide variation in the
pharmacokinetics of lumefantrine among individuals
[24]. The maximum therapeutic cure rate is achieved
when the plasma drug concentration is adequately avail-
able for at least three parasite life cycles that is equal tomber of gametocytes per 500 WBC
3 Day 7 D ay 14 Day 21 Day 28
0 0 0 0
5 0 0 0
28 0 0 0
2 0 0 0
4 0 0 0
2 2 0 0
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on selection for resistance to residual parasites in high
transmission areas needs to be carefully evaluated.
Artemether-lumefantrine showed short fever and para-
sites clearence time and quick recovery of haemoglobin
levels. Only one patient had fever up to Day 1 and neither
fever nor parasitaemia was reported on Day 2, contrary to
a report in central Ethiopia where fever and parasitaemia
persisted to Day 3 [26]. Haemoglobin levels significantly
increased on Day 7 as reported in other studies in this re-
gion, but the second haemoglobin measurement was done
on Day 14 [27,28]. The complete 28 days’ follow up to all
patients was achieved by using mobile phone calls to re-
mind parents or guardians about their appointment dates
and days. Mobile phone contacts might minimize loss to
follow up in efficacy studies.
The Day 0 gametocyte prevalence (30%) recorded in
this study is higher compared with those reported previ-
ously in Tanzania [29,30]. Furthermore, as observed else-
where in Africa [27,31-33], no new gametocytaemic
cases were observed during the follow-up period. Admit-
tedly, this could be attributable to small sample size,
which is a limitation of this study, and microscopy
detection limit. Gametocytaemia persisted for seven to
14 days, (as recorded previously), against 55 days for
non-ACT drugs [34].
ACT is effective against immature sequestered gameto-
cytes [32,34,35], hence they reduce gametocyte carriage as
well as gametocytes density [31,36,37]. Apparently, ACT
does not affect the viability of mature gametocytes [31,36].
Consequently, persistence of mature gametocytes might
still play a role on maintianing transmission cycle. Hence,
combination with a strong gametocytocidal drug such as
primaquine will maximize ACT usefulness.
The phenomenon of increase in gametocytaemia in
this study and of sexual stage count in Nigeria [38] des-
pite drug treatment, might be a sign of tolerance or
emergence of parasites with reduced drug sensitivity in
the region. Another plausible explanation for the in-
crease in gametocytaemia is coincidence between drug
administration and maturation release of mature game-
tocytes into the peripheral circulation. These observa-
tions of increased gametocytaemia after treatment need
to be verified in a larger study.Conclusion
The therapeutic efficacy of AL against uncomplicated
P. falciparum malaria was high in the study area. All
patients were not exposed to AL prior to hospital pres-
entation and levels of lumefantrine on Day 7 were thera-
peutically adequate but highly variable. The unusual
increase in gametocytes following treatment needs be
evaluated in a larger study concurrent with improvementcapacity to diagnose malaria and handling of non-
malarial fevers.
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